No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 1,919 | 2,733 | 3,411 | 2,821 | 3,441 | 3,612 | 3,680 | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 28 | 28 | 306 | -175 | 41 | 95 | 109 | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Brother Enterprises Holding Co.,Ltd. is a diversified Chinese enterprise specializing in the manufacturing and global distribution of chemicals. The company operates through four principal business segments: Leather Chemicals, Vitamins, Flavors and Fragrances, and Active Pharmaceutical Ingredients (APIs). Within its Vitamins division, Brother Enterprises supplies a range of nutritional additives, including vitamin K3, vitamin B1, nicotinamide, niacin, vitamin B5, and alanine. The Leather Chemicals segment provides essential materials for the leather industry, such as chrome tanning agents, retanning agents, fatliquors, and various specialized additives. Under its API portfolio, the company manufactures contrast agent APIs, topiroxostat, and bespoke active pharmaceutical ingredients and intermediates tailored for therapeutic areas such as endocrine and metabolism disorders, nervous system conditions, and respiratory ailments. The Flavors and Fragrances division produces synthetic aromatic compounds like vanillin and ethyl vanillin, alongside other synthetic fragrances. These products find application in the food, daily chemical, and other industrial sectors. This segment also supplies turpentine. Furthermore, Brother Enterprises manufactures molecular sieves and catalysts, as well as several chromium-based compounds, including sodium dichromate, chromic acid, and additional chrome tanning agents. Established in 1991, the company was originally known as Haining Leather Chemicals Factory. Its headquarters are located in Haining, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Brother Enterprises Holding Co.,Ltd. (002562.SZ)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Brother Enterprises Holding Co.,Ltd. is a diversified Chinese enterprise specializing in the manufacturing and global distribution of chemicals. The company operates through four principal business segments: Leather Chemicals, Vitamins, Flavors and Fragrances, and Active Pharmaceutical Ingredients (APIs). Within its Vitamins division, Brother Enterprises supplies a range of nutritional additives, including vitamin K3, vitamin B1, nicotinamide, niacin, vitamin B5, and alanine. The Leather Chemicals segment provides essential materials for the leather industry, such as chrome tanning agents, retanning agents, fatliquors, and various specialized additives. Under its API portfolio, the company manufactures contrast agent APIs, topiroxostat, and bespoke active pharmaceutical ingredients and intermediates tailored for therapeutic areas such as endocrine and metabolism disorders, nervous system conditions, and respiratory ailments. The Flavors and Fragrances division produces synthetic aromatic compounds like vanillin and ethyl vanillin, alongside other synthetic fragrances. These products find application in the food, daily chemical, and other industrial sectors. This segment also supplies turpentine. Furthermore, Brother Enterprises manufactures molecular sieves and catalysts, as well as several chromium-based compounds, including sodium dichromate, chromic acid, and additional chrome tanning agents. Established in 1991, the company was originally known as Haining Leather Chemicals Factory. Its headquarters are located in Haining, China.